Company / Cash & Equivalents
NEPHROS INC Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$5.4M
FY2025
5-year range
$3.6M / $7.0M
FY2021-FY2025
Trend
+43.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 7 years, ranging from $4M in FY2022 to $8M in FY2020.
Based on SEC 10-K filings.
$5M in FY2025 with a 5-year CAGR of -8.1%.
Improved from $4M to $5M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +14.1%
- 5-Year CAGR
- -8.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -8.1%, indicating a declining trend.
- In FY2025, cash & equivalents increased 43.6% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -5.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.4M | +43.6% |
| FY2024 | $3.8M | -12.7% |
| FY2023 | $4.3M | +18.5% |
| FY2022 | $3.6M | -47.9% |
| FY2021 | $7.0M | -15.5% |
| FY2020 | $8.2M | +98.0% |
| FY2019 | $4.2M | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026